TRON CoVigator Reveals Evolution of Spike-glycoprotein Mutations in Covid-19 Virus

Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON) is a biopharmaceutical research organization pursuing new diagnostics and drugs for the treatment of cancer and other diseases. TRON applied its expertise in cancer immuno-biology research to the Covid-19 pandemic by analyzing hundreds of thousands of SARS-CoV-2 genome samples for variants in its spike protein. To carry out the gene sequence analysis tasks, TRON needed to extend its computational capacity. They acquired Intel® Server System nodes built with 2nd Gen Intel Xeon® Scalable processors to run their CoVigator genome analysis pipelines. The new cluster allowed them to analyze nearly 2 million virus genomes and over 30,000 virus genome sequencing datasets, discovering many variants of the spike protein.[1]

Products and Solutions
2nd Gen Intel® Xeon® Scalable processors
Intel® Server System R1000WF Family
Intel® SSD D3-S4610 Series

Industry
Biotechnology

Organization Size
51-200

Country
Germany

Partners
primeLine Solutions

Learn more
Case Study

1 For more complete information about performance and benchmark results, visit https://www.intel.com/content/www/us/en/customer-spotlight/stories/tron-customer-story.html